On Tuesday, Shares of Hewlett-Packard Company (NYSE:HPQ), lost -0.93% to $27.80.
Hewlett-Packard Company, unveiled the expansion of its rapidly growing Instant Ink replacement service to its new HP ENVY, OfficeJet and DeskJet printers. The new printers come HP Instant Ink ready and offer a choice of monthly and yearly ink subscription plans starting at only $2.99 a month.
With HP Instant Ink, customers select a plan based on how much they want to print and HP takes care of the rest. You never run out of ink, and printing costs up to 50 percent less.(1) Eliminating the anxiety of running out of ink at the worst time, the new fall line comes with smart cartridges in the box that can reorder ink before they run out and deliver it directly to the customer’s door.
“Customers want printing to be affordable, convenient and meaningful,” said Stephen Nigro, senior vice president, Imaging and Printing, HP. “With HP Instant Ink, customers can enjoy low cost of ownership and print what matters most to them without the worry of running out of ink or spending too much.”
Hewlett-Packard Company, together with its auxiliaries, provides products, technologies, software, solutions, and services to individual consumers and small- and medium-sized businesses (SMBs), in addition to to the government, health, and education sectors worldwide.
Shares of Dow Chemical Co (NYSE:DOW), declined -4.71% to $41.70, during its last trading session.
Dow AgroSciences LLC, a wholly owned partner of The Dow Chemical Company (DOW), has reached a partnership agreement with the Institute of Crop Sciences of the Chinese Academy of Agricultural Sciences (ICS-CAAS). Under the agreement, Dow AgroSciences grants ICS-CAAS a royalty-free, non-transferable research and commercialization license for its proprietary EXZACT™ Precision Genome Editing Technology to be used in rice in China. Dow AgroSciences and ICS-CAAS scientists will collaboratively develop an industry-leading rice genome editing technology platform.
ICS-CAAS indicates this partnershipis a milestone, which will accelerate the development of rice genome editing technology platform in China. It will have noteworthyimpact in developing new agronomic traits in rice.
“Our partnership with ICS-CAAS, a world-renowned agricultural science research organization, is one with great promise,” said Tim Hassinger, President and CEO of Dow AgroSciences. “We have a long-term commitment in China as a planned partner for agricultural sustainability and best practices. The EXZACT Precision Technology partnershipwith CAAS is a strong example of this commitment, which will significantly enable Chinese scientists to improve rice research and product development, thus benefiting China’s long term food security.”
The Dow Chemical Company manufactures and supplies products that are used primarily as raw materials in the manufacture of customer products and services worldwide. It operates through Agricultural Sciences, Consumer Solutions, Infrastructure Solutions, Performance Materials & Chemicals, and Performance Plastics segments.
Finally, Celgene Corporation (NASDAQ:CELG), ended its last trade with -2.22% loss, and closed at $115.26.
Celgene Corporation (CELG) declared it has closed its acquisition of Receptos, Inc. Receptos stockholders received $232.00 per share in cash, for a total of about $7.2 billion, net of cash attained. As a result of the completion of the merger, the common stock of Receptos is no longer listed for trading on the NASDAQ Global Market or any other exchange and trading ceased at the close of the markets on Thursday, August 27, 2015.
Receptos stockholders who hold shares through a bank or broker will not have to take any action to have their shares converted into cash, since these conversions will be handled by the bank or broker. Stockholders who hold stock certificates can surrender their certificates for $232.00 per share in cash, without interest and less any applicable withholding taxes, through the paying agent for the merger, American Stock Transfer & Trust Company, LLC.
The acquisition of Receptos significantly enhances Celgene’s Inflammation & Immunology (I&I) portfolio, further diversifies the Company’s predictable revenue startning in 2019, and builds upon Celgene’s growing expertise in inflammatory bowel disease (IBD). The transaction adds Ozanimod, a novel, potential best-in-class, oral, selective sphingosine 1-phosphate 1 and 5 receptor modulator (S1P) to Celgene’s deep and diverse pipeline of potential disease-altering medicines and investigational compounds.
Celgene has a strong scientific foundation in inflammation and immunology that covers a broad spectrum of diseases. Anchored by the successful global launch of OTEZLA® (apremilast) in psoriasis and psoriatic arthritis, and new opportunities for expansion as a result of the addition of the Receptos programs, Celgene’s I&I pipeline now comprises of three high-potential commercialized or late-stage assets; OTEZLA, GED-0301 and Ozanimod. All three candidates are in phase III development and encompass four indications: Behçet’s disease, Crohn’s disease (CD), UC and RMS. The pipeline also comprises seven molecules in phase II development in a variety of indications, counting RPC4046 for eosinophilic esophagitis (EoE), and a growing number of phase I and preclinical assets.
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases in the United States and Internationally. It markets REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell lymphoma; ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers; POMALYST/IMNOVID for the treatment of multiple myeloma; and VIDAZA, a pyrimidine nucleoside analog to treat intermediate-2 and high-risk MDS, and chronic myelomonocytic leukemia, in addition to acute myeloid leukemia (AML).
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
